Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer, Pancreatic Cancer
Conditions
Keywords
PCI-27483, Factor VIIa, Gemcitabine, 4 months life expectancy, Pharmacyclics, Locally Advanced, Metastatic disease
Brief summary
The purpose of this study is to evaluate the safety and tolerability of selected dose 1.2mg/kg BID dosage administered subcutaneously (SC) administered PCI-27483 to metastatic or locally advanced pancreatic cancer patients receiving concurrent therapy with intravenously administered gemcitabine for 12 weeks.
Detailed description
This study will be conducted in three segments: Part A, Part B and Part C. Parts A and B are 12 weeks of treatment followed by 4 weeks of evaluation. In part A patients will dose-escalate up to three dose levels of PCI-27483 administered as subcutaneous (SC) injections twice-daily (BID). Part B to start once 4th patient completes 90 of 112 doses in 8 weeks. In part B patients are randomized to PCI-27483 and gemcitabine (active arm) OR gemcitabine only (control arm). PCI-27483 doses in both Part A and B will be administered in combination with a standard regimen of gemcitabine. Patients with a tumor response or stable disease at 12 weeks will have the opportunity to continue PCI-27483 treatment until disease progression or the Investigator considers the study treatment to be no longer tolerable. Treatment with gemcitabine in either the active or control arm may continue until a standard course of gemcitabine therapy has been completed. Patients will complete Part A or Part B after 16 weeks on study regardless of treatment duration. Evaluable patients will roll over into part C and be followed for 12 months from enrollment (first dose).
Interventions
DRUGPCI-27483
Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care. All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are \>3.50,a reduced dosage will be calculated.
DRUGGemcitabine
Sponsors
Pharmacyclics LLC.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Men or women at least 18 years old 2. Body weight ≥ 40 and ≤ 100 kg. 3. Part A: Metastatic ductal adenocarcinoma of the pancreas diagnosed ≤ 4 months prior to enrollment. (Locally advanced does not have any criteria) 4. Part B: Locally advanced ductal adenocarcinoma of the pancreas diagnosed ≤ 3 months prior to enrollment or metastatic ductal adenocarcinoma diagnosed ≤ 2 months. 5. Measurable disease by spiral CT scan (SCT) in accordance with RECIST criteria. 6. Patients after non-curative surgery are eligible if at least 4 weeks after surgery and recovered from significant surgical morbidity. 7. Estimated life expectancy of at least 4 months. 8. ECOG performance status 0 to 1. 9. Normal baseline coagulation function as defined by: 1. PT 10-16 seconds, and 2. aPTT 22-38 seconds. 10. Agree to not participate in contact sports or strenuous activity while taking PCI-27483. 11. Ability to understand the study, willingness to participate in the study for the study duration, and ability to provide written informed consent to participate.
Exclusion criteria
1. History of any clinically significant medical condition that, in the opinion of the Principal Investigator, would interfere with the study evaluation or interpretation. 2. Known history of brain metastases. 3. Any evidence of intra-cranial hemorrhage based on head CT scan within 30 days of enrollment. 4. History of disease progression while being treated with gemcitabine. 5. Radiotherapy of the primary tumor or unwillingness to defer radiotherapy of the primary tumor until \> 3 months from initiation of treatment. 6. History of venous thromboembolism (eg, deep vein thrombosis, pulmonary embolism,and arterial thromboembolism) or other indications for anticoagulant treatment (eg,mechanical heart values, atrial fibrillation, etc.) within the last year. Local thrombus in the mesenteric or portal vein is acceptable. 7. Uncontrolled hypertension (systolic \> 160 or diastolic \> 100 mm Hg on medical treatment). 8. Continued anticoagulation therapy or anticoagulation therapy within 2 months prior to enrollment, except for perisurgical prophylaxis which must have ceased 2 weeks before enrollment. 9. Contraindication to systemic anticoagulation. 10. Continued treatment with antiplatelet drugs including aspirin, clopidogrel, etc. within the past 72 hours. 11. Known history of clinically significant or recurrent bleeding episodes, including significant bleeding after surgery, childbirth, or dental extraction. 12. Patients with documented invasion of adjacent organs by CT scan (e.g. stomach, duodenum) are not eligible 13. Patients known to have esophageal varicose are not eligible 14. Known history of a congenital coagulation factor deficiency. 15. Known acquired or hereditary platelet disorder. 16. Known history of immunodeficiency. 17. Women of child-bearing potential or sexually active men, unwilling to use adequate contraceptive protection during the course of the study. 18. Pregnant or lactating women (female patients of childbearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or if positive, pregnancy ruled out by ultrasound). 19. Laboratory Abnormalities: 1. Serum creatinine \> 2 mg/dL or creatinine clearance \< 50 mL/minute (using Cockroft Gault formula) 2. AST and ALT ≥ 4.0 x upper limit of normal (ULN). 3. Bilirubin ≥ 3 mg/dL. 4. Alkaline phosphatase \> 5 x ULN. 5. Albumin \< 2.0g/dL. 6. Hemoglobin \< 9.0 g/dL. 7. Platelet count \< 100,000/μL. 20. Evidence of active gastrointestinal tract bleeding, including guaiac stool positivity,excluding hemorrhoidal bleeding 21. Chronic active hepatitis B or C. 22. Known HIV infection. 23. Participation in any study of an investigational device, medication, biologic, or other agent within 30 days prior to enrollment, or planned participation within the study duration. 24. Risk factors for, or use of medications known to prolong QTc interval or that may be associate with Torsades de Pointes within 7 days of treatment start (see Appendix J. Risk Factors for Drug-induced Torsades de Pointes). 25. QTc prolongation (defined as a QTc ≥ 450 msec) or other significant ECG abnormalities including 2nd degree AV block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min). If 2 screening ECGs have a QTc ≥ 450 msec, the ECGs can be submitted for a centralized, cardiologic evaluation and if determined to be \< 450 msec then the patient is eligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (AEs) | First dose until 28 days after last dose of PCI-27483 or gemcitabine whichever occurs last in the assigned part (A or B). | Clinically meaningful toxicity adverse events will be defined in accordance with by CTCAE v3.0 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| (PCI-27483 + Gemcitabine)/Part A | 8 |
| (PCI-27483 + Gemcitabine)/Part B | 18 |
| Gemcitabine/Part B | 16 |
| Total | 42 |
Baseline characteristics
| Characteristic | (PCI-27483 + Gemcitabine)/Part A | (PCI-27483 + Gemcitabine)/Part B | Gemcitabine/Part B | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 3 Participants | 5 Participants | 6 Participants | 14 Participants |
| Age, Categorical Between 18 and 65 years | 5 Participants | 13 Participants | 10 Participants | 28 Participants |
| Region of Enrollment United States | 8 participants | 18 participants | 16 participants | 42 participants |
| Sex: Female, Male Female | 4 Participants | 7 Participants | 6 Participants | 17 Participants |
| Sex: Female, Male Male | 4 Participants | 11 Participants | 10 Participants | 25 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 8 / 8 | 18 / 18 | 16 / 16 |
| serious Total, serious adverse events | 5 / 8 | 12 / 18 | 7 / 16 |
Outcome results
Primary
Number of Participants With Treatment Emergent Adverse Events (AEs)
Clinically meaningful toxicity adverse events will be defined in accordance with by CTCAE v3.0
Time frame: First dose until 28 days after last dose of PCI-27483 or gemcitabine whichever occurs last in the assigned part (A or B).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| (PCI-27483 + Gemcitabine)/Part A | Number of Participants With Treatment Emergent Adverse Events (AEs) | 8 participants |
| (PCI-27483 + Gemcitabine)/Part B | Number of Participants With Treatment Emergent Adverse Events (AEs) | 18 participants |
| Gemcitabine/Part B | Number of Participants With Treatment Emergent Adverse Events (AEs) | 16 participants |